0000890465-13-000025.txt : 20130930
0000890465-13-000025.hdr.sgml : 20130930
20130930182338
ACCESSION NUMBER: 0000890465-13-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130926
FILED AS OF DATE: 20130930
DATE AS OF CHANGE: 20130930
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nader Francois
CENTRAL INDEX KEY: 0001365343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 131124521
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2013-09-26
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001365343
Nader Francois
550 HILLS DRIVE
BEDMINSTER
NJ
07921
1
1
0
0
President, CEO and Director
Common Stock
2013-09-26
4
M
0
19350
5.05
A
236828
D
Common Stock
2013-09-26
4
M
0
992
5.85
A
237820
D
Common Stock
2013-09-26
4
S
0
143503
33.07
D
94317
D
Common Stock
2013-09-26
4
S
0
6497
33.60
D
87820
D
Common Stock
2013-09-27
4
M
0
17008
5.85
A
104828
D
Common Stock
2013-09-27
4
M
0
16650
6.16
A
121478
D
Common Stock
2013-09-27
4
M
0
9800
5.71
A
131278
D
Common Stock
2013-09-27
4
S
0
43458
32.3558
D
87820
D
Stock Options
5.05
2013-09-26
4
M
0
19350
0
D
2018-07-15
Common Stock
19350
3150
D
Stock Options
5.85
2013-09-26
4
M
0
992
0
D
2018-10-15
Common Stock
992
21508
D
Stock Options
5.85
2013-09-27
4
M
0
17008
0
D
2018-10-15
Common Stock
17008
4500
D
Stock Options
6.16
2013-09-27
4
M
0
16650
0
D
2019-01-15
Common Stock
16650
5850
D
Stock Options
5.71
2013-09-27
4
M
0
9800
0
D
2019-01-20
Common Stock
9800
82826
D
The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective September 26, 2013.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $32.51 and $33.50. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $33.52 and $33.69. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $32.05 and $32.77. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
On July 15, 2008, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter.
On October 15, 2008, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter.
On January 15, 2009, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter.
On January 20, 2009, the Reporting Person received a grant of performance based options under the Issuer's 1998 Stock Option Plan. The actual number of options received was 92,626, which was determined based on the performance of the Issuer's common stock relative to the performance of stock comprising a selected market index. 50% of such options vested and became exercisable on the second anniversary of the date of grant and the remaining 50% of such options vested and became exercisable on the third anniversary of the date of grant.
/s/ Francois Nader, by Edward Stratemeier as attorney-in-fact
2013-09-30